News

King Pharmaceuticals has posted total revenues of $380.85m for the first quarter, 2010, compared to $429m for the prior year period. Operating income was $27.46m, compared to $7.1m

The license granted by GTG covers the activities of EraGen in relation to its genetic diagnostic and analysis products, limited to US and Canada. Although not a counterparty

As a result of the acquisition, DSM Biologics will gain all rights for the commercialisation of the Rhobust technology in various fields, including the pharma industry. The Rhobust

Antares’ delivery device, branded as Tjet is used to deliver Tev-Tropin brand human growth hormone (hGH) to children who have growth failure due to inadequate secretion of normal

The SmartChip System is designed to advance genome research results through the improved discovery and validation of biomarkers enabled by its high-throughput capability. WaferGen said that it currently

The expanded agreement builds upon the development and commercialisation collaboration between the two companies announced in January 2009. Onyx Pharmaceuticals is expected to provide $20m in funding to

EndoCeutics will be responsible for conducting the Phase III studies for Vaginorm. Thereafter, Bayer will be responsible for the registration and commercialization of Vaginorm. Under the terms of

DSM Biologics said that, by increasing the cell density and optimising the conditions for protein production of a culture, its proprietary XD Technology offers a simple, elegant solution

Particle Sciences said that MRT technology combines a high shear, high pressure impinging jet processor with expert process development to generate results in bottom-up nanoparticle creation and continuous